Elegrobart Phase 3 REVEAL-1 Trial Meets Primary Endpoint in Active Thyroid Eye Disease

summarizeSummary

Viridian Therapeutics announced positive Phase 3 results for elegrobart in active thyroid eye disease, meeting its primary endpoint with high statistical significance and showing a favorable safety profile, positioning it as a potential first-in-class subcutaneous treatment.

check_boxKey Events

• Elegrobart Phase 3 REVEAL-1 Trial Success

  The REVEAL-1 clinical trial for elegrobart in active thyroid eye disease met its primary endpoint with high statistical significance (p < 0.0001) at week 24.

• Clinically Meaningful Efficacy

  Elegrobart achieved a 54% proptosis responder rate (Q4W) and 63% (Q8W) versus 18% for placebo, with 51% complete resolution of diplopia in the Q4W arm versus 16% placebo.

• Favorable Safety Profile

  The drug was generally well-tolerated, with low rates of hearing impairment (tinnitus) and no associated reductions in hearing.

• Pipeline Advancement and Financial Strength

  The company anticipates a Biologics License Application (BLA) submission for elegrobart in Q1 2027, following REVEAL-2 data in Q2 2026. Viridian also reported $875 million in cash as of Q4 2025, sufficient to fund operations through profitability.

auto_awesomeAnalysis

This 8-K announces highly positive topline results from the Phase 3 REVEAL-1 clinical trial for elegrobart in active thyroid eye disease (TED). The drug met its primary endpoint with high statistical significance, demonstrating robust proptosis responses and clinically meaningful improvements in diplopia. The favorable safety profile and potential for elegrobart to be the first subcutaneous autoinjector for TED represent a significant advancement and market opportunity. This successful trial de-risks a key pipeline asset and strengthens Viridian's position in the TED market, complementing its other late-stage candidate, veligrotug.